BioCentury | Apr 27, 2009
Clinical News

Lulicon luliconazole: Phase II started

...Topica (formerly Janus Pharmaceuticals Inc. ) began a double-blind, vehicle-controlled, U.S. Phase II trial to evaluate 1% luliconazole...
BioCentury | Jun 23, 2008
Company News

Creabilis management update

...Italy Business: Inflammation, autoimmune and dermatology Hired: Tony Wilson as CEO, formerly a consultant at Janus Pharmaceuticals Inc. WIR...
BioCentury | Apr 9, 2007
Company News

Janus, Nihon Nohyaku deal

...luliconazole to treat tinea pedis and onychomycosis in the U.S. Financial terms were not disclosed. Janus Pharmaceuticals Inc....
BioCentury | Dec 11, 2006
Clinical News

Sorivudine: Phase II data

...first month, as evaluated by the Brief Pain Inventory (BPI). aRigen Inc. , Tokyo, Japan Janus Pharmaceuticals Inc....
BioCentury | Apr 11, 2005
Clinical News

JA-001: IND submitted

...an open-label, U.S. Phase I trial in 16 healthy volunteers. aRigen Inc. , Tokyo, Japan Janus Pharmaceuticals Inc....
BioCentury | Oct 31, 2000
Financial News

Vela raises $16.3 million

...Investors included New Enterprise Associates; Venrock Associates; Johnston Associates; and MBF Capital. Vela , formerly Janus Pharmaceuticals...
Items per page:
1 - 6 of 6
BioCentury | Apr 27, 2009
Clinical News

Lulicon luliconazole: Phase II started

...Topica (formerly Janus Pharmaceuticals Inc. ) began a double-blind, vehicle-controlled, U.S. Phase II trial to evaluate 1% luliconazole...
BioCentury | Jun 23, 2008
Company News

Creabilis management update

...Italy Business: Inflammation, autoimmune and dermatology Hired: Tony Wilson as CEO, formerly a consultant at Janus Pharmaceuticals Inc. WIR...
BioCentury | Apr 9, 2007
Company News

Janus, Nihon Nohyaku deal

...luliconazole to treat tinea pedis and onychomycosis in the U.S. Financial terms were not disclosed. Janus Pharmaceuticals Inc....
BioCentury | Dec 11, 2006
Clinical News

Sorivudine: Phase II data

...first month, as evaluated by the Brief Pain Inventory (BPI). aRigen Inc. , Tokyo, Japan Janus Pharmaceuticals Inc....
BioCentury | Apr 11, 2005
Clinical News

JA-001: IND submitted

...an open-label, U.S. Phase I trial in 16 healthy volunteers. aRigen Inc. , Tokyo, Japan Janus Pharmaceuticals Inc....
BioCentury | Oct 31, 2000
Financial News

Vela raises $16.3 million

...Investors included New Enterprise Associates; Venrock Associates; Johnston Associates; and MBF Capital. Vela , formerly Janus Pharmaceuticals...
Items per page:
1 - 6 of 6